A first look [BE/BA News]

posted by BRB  – Canada, 2022-12-02 19:20 (110 d 08:01 ago) – Posting: # 23379
Views: 2,972

Hi J,
No, it's still there. See lines 260-261:

The number of evaluable subjects in a PK BE study should not be less than 12. For highly variable drug products, a minimum of 24 subjects are recommended for BE assessment.

❝ Almost a complete overhaul. Very detailed. I notice something, they removed the min sample size requirement of n=12 (Unless it's written in later part of the doc)


Complete thread:

UA Flag
Activity
 Admin contact
22,548 posts in 4,723 threads, 1,606 registered users;
18 visitors (0 registered, 18 guests [including 11 identified bots]).
Forum time: 03:21 CET (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5